Home Cart Sign in  
Chemical Structure| 1702809-17-3 Chemical Structure| 1702809-17-3

Structure of THZ531
CAS No.: 1702809-17-3

Chemical Structure| 1702809-17-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

THZ531 is a covalent CDK12 and CDK13 inhibitor with IC50s of 158 nM and 69 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of THZ531

CAS No. :1702809-17-3
Formula : C30H32ClN7O2
M.W : 558.07
SMILES Code : O=C(NC1=CC=C(C(N2C[C@H](NC3=NC=C(Cl)C(C4=CNC5=C4C=CC=C5)=N3)CCC2)=O)C=C1)/C=C/CN(C)C
MDL No. :MFCD31563595
InChI Key :RUBYHLPRZRMTJO-MOVYNIQHSA-N
Pubchem ID :118025540

Safety of THZ531

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of THZ531

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
REC-1 1.63 μM 72 hours REC-1 cells are resistant to THZ531, and MDR1 upregulation drives THZ531 resistance. Haematologica. 2022 May 1;107(5):1119-1130.
ONS-76 50-100 nM 72 hours Evaluate the effect of THZ531 on the viability of SHH MB cells, results showed low sensitivity of ONS-76 cells to THZ531 J Exp Clin Cancer Res. 2023 Aug 21;42(1):214.
MED-411 50-100 nM 72 hours Evaluate the effect of THZ531 on the viability of Group 3 MB cells, results showed high sensitivity of MED-411 cells to THZ531 J Exp Clin Cancer Res. 2023 Aug 21;42(1):214.
HD-MBO3 50-100 nM 72 hours Evaluate the effect of THZ531 on the viability of Group 3 MB cells, results showed high sensitivity of HD-MBO3 cells to THZ531 J Exp Clin Cancer Res. 2023 Aug 21;42(1):214.
D341 50-100 nM 72 hours Evaluate the effect of THZ531 on the viability of Group 3 MB cells, results showed high sensitivity of D341 cells to THZ531 J Exp Clin Cancer Res. 2023 Aug 21;42(1):214.
D283 50-100 nM 72 hours Evaluate the effect of THZ531 on the viability of Group 3 MB cells, results showed high sensitivity of D283 cells to THZ531 J Exp Clin Cancer Res. 2023 Aug 21;42(1):214.
DAOY 50-100 nM 72 hours Evaluate the effect of THZ531 on the viability of SHH MB cells, results showed low sensitivity of DAOY cells to THZ531 J Exp Clin Cancer Res. 2023 Aug 21;42(1):214.
TC32 cells 100 nM and 500 nM 6 hours THZ531 treatment significantly downregulated the expression of DNA damage repair-related genes, including BRCA1, RAD51, FANCF, and XRCC2. Cancer Cell. 2018 Feb 12;33(2):202-216.e6.
A673 cells 100 nM and 500 nM 6 hours THZ531 treatment significantly downregulated the expression of DNA damage repair-related genes, including BRCA1, RAD51, FANCF, and XRCC2. Cancer Cell. 2018 Feb 12;33(2):202-216.e6.
OVCAR-3 cells 200 nM 6 hours THZ531 treatment leads to retention of proximal introns, affecting gene expression Nucleic Acids Res. 2023 Jun 23;51(11):5512-5526.
MDA-MB-231 cells 50 nM 6 hours THZ531 combined with PdB showed synergistic effects, enhancing proximal intron retention Nucleic Acids Res. 2023 Jun 23;51(11):5512-5526.
MiaPaCa-2 cells 200 nM 3 hours THZ531 inhibits CDK12/13 activity, reduces RNAPII Ser2 phosphorylation, and affects the interaction between SF3B1 and RNAPII, thereby impacting splicing Nucleic Acids Res. 2023 Jun 23;51(11):5512-5526.
HAP1 cells 300 nM 72 hours To evaluate the effect of THZ531 on HAP1 cell proliferation, results showed that THZ531 significantly inhibited cell proliferation at 300 nM concentration. Nat Chem Biol. 2016 Oct;12(10):876-84.
Jurkat cells 50 nM 6 hours To evaluate the effect of THZ531 on Jurkat cell proliferation, results showed that THZ531 significantly inhibited cell proliferation at 50 nM concentration. Nat Chem Biol. 2016 Oct;12(10):876-84.
Val 100 nM 6 and 24 hours THZ531 leads to inhibition of oncogenic transcriptional programs, especially the DNA damage response pathway, MYC target genes and the mTOR-4EBP1-MCL-1 axis, contributing to dramatic lymphoma suppression in vitro. Haematologica. 2022 May 1;107(5):1119-1130.
DOHH-2 100 nM 6 and 24 hours THZ531 leads to inhibition of oncogenic transcriptional programs, especially the DNA damage response pathway, MYC target genes and the mTOR-4EBP1-MCL-1 axis, contributing to dramatic lymphoma suppression in vitro. Haematologica. 2022 May 1;107(5):1119-1130.
Jeko-1 100 nM 6 and 24 hours THZ531 leads to inhibition of oncogenic transcriptional programs, especially the DNA damage response pathway, MYC target genes and the mTOR-4EBP1-MCL-1 axis, contributing to dramatic lymphoma suppression in vitro. Haematologica. 2022 May 1;107(5):1119-1130.
Z138 100 nM 6 and 24 hours THZ531 leads to inhibition of oncogenic transcriptional programs, especially the DNA damage response pathway, MYC target genes and the mTOR-4EBP1-MCL-1 axis, contributing to dramatic lymphoma suppression in vitro. Haematologica. 2022 May 1;107(5):1119-1130.
22Rv1 cells 200 nM 6 hours To evaluate the transcriptomic effects of THZ531 on CRPC cells 22Rv1, results showed that THZ531 regulated a large percentage of genes at the gene expression level, particularly in transcriptional and splicing regulation. J Exp Clin Cancer Res. 2024 Feb 27;43(1):58.
OVCAR3 cells 200 nM 6 hours To assess the effects of THZ531 on the transcriptome of HGSOC cells, results showed that THZ531 significantly altered the expression of 35% of genes. J Exp Clin Cancer Res. 2023 May 18;42(1):126.
Hela 50 nM 24 hours THZ531 inhibits CDK12 and CDK13, enhances intronic polyadenylation (IPA) of PD-L1, thereby reducing full-length PD-L1 expression and increasing PD-L1-v4 expression. J Immunother Cancer. 2023 May;11(5):e006483.
A375 200 nM 24 hours THZ531 inhibits CDK12 and CDK13, enhances intronic polyadenylation (IPA) of PD-L1, thereby reducing full-length PD-L1 expression and increasing PD-L1-v4 expression. J Immunother Cancer. 2023 May;11(5):e006483.
LNCaP and C4–2 cells 0.2, 0.5 µM 7 days Sphere-formation assays showed reduced sphere-forming ability and number in THZ531-treated cells Cell Death Dis. 2021 Jul 27;12(8):740.
C4–2 cells 1.0 µM 6 hours A conspicuous reduction in the amount of newly transcribed RNA was observed using fluorescently labeled EU incorporation assays Cell Death Dis. 2021 Jul 27;12(8):740.
LNCaP cells 0.2, 0.5, 1.0 µM 6 hours To evaluate the effect of THZ531 on the transcriptome, results showed a global and concentration-dependent reduction in steady-state mRNA Cell Death Dis. 2021 Jul 27;12(8):740.
A375 cells 0.05, 0.1, 0.2, 0.5 and 1 µM 2 hours To evaluate the effect of THZ531 on cyclin K levels, it was found that THZ531 does not promote cyclin K degradation. Cell Death Discov. 2023 Dec 16;9(1):459.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.79mL

0.36mL

0.18mL

8.96mL

1.79mL

0.90mL

17.92mL

3.58mL

1.79mL

References

 

Historical Records

Categories